Effects of Fasudil and Different Doses of Rosuvastatin on Coronary Slow Flow
1.No.1 Cardiovascular Department,the First Hospital of Hebei Medical University,Shijiazhuang 050031,China
2.No.3 Cardiovascular Department,the First Hospital of Shijiazhuang,Shijiazhuang 050011,China
3.No.2 Geriatric Department,Aerospace Center Hospital,Beijing 100040,China
*Corresponding author:ZHENG Mei,Associate chief physician;E-mail:bayi81@126.com
LI Lizhuo,ZHENG Mei,LI Weicong, et al. Effects of Fasudil and Different Doses of Rosuvastatin on Coronary Slow Flow [J]. Chinese General Practice, 2019, 22(34): 4251-4255. DOI: 10.12114/j.issn.1007-9572.2019.00.693.
李立卓,郑梅,李伟聪等. 法舒地尔联合不同剂量瑞舒伐他汀对冠状动脉慢血流的影响[J]. 中国全科医学, 2019, 22(34): 4251-4255. DOI: 10.12114/j.issn.1007-9572.2019.00.693.
[1]FINESCHI M,GORI T.Coronary slow-flow phenomenon or syndrome Y:a microvascular angina awaiting recognition[J].J Am Coll Cardiol,2010,56(3):239-240.DOI:10.1016/j.jacc.2009.09.082.
[2]MUTLUER F O,URAL D,GüNG?R B,et al.Association of interleukin-1 gene cluster polymorphisms with coronary slow flow phenomenon[J].Anatol J Cardiol,2018,19(1):34-41.DOI:10.14744/AnatolJCardiol.2017.8071.
[3]CAMSARI A,OZCAN T,OZER C,et al.Carotid artery intima-media thickness correlates with intravascular ultrasound parameters in patients with slow coronary flow[J].Atherosclerosis,2008,200(2):310-314.DOI:10.1016/j.athero- sclerosis.2007.12.028.
[4]SANTOS G L,HARTMANN S,ZIMMERMANN W H,et al.Inhibition of Rho-associated kinases suppresses cardiac myofibroblast function in engineered connective and heart muscle tissues[J].J Mol Cell Cardiol,2019,134:13-28.DOI:10.1016/j.yjmcc.2019.06.015.
[5]李建军.他汀类药物非调脂作用及其机制(续9-1)[J].中国循环杂志,2011,26(2):155.DOI:10.3969/j.isma.1000-3614.2011-02-021.http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgxhzz201102024.
[6]GIBSON C M,SCHOMIG A.Coronary and myocardial angiograph:angiographic assessment of both epicardial and myocardial perfusion[J].Circulation,2004,109(25):3096-3105.DOI:10.1161/01.CIR.0000134278.50359.CB.
[7]LEUNG T,MANSER E,TAN L,et al.A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes[J].J Biol Chem,1995,270(49):29051-29054.DOI:10.1074/jbc.270.49.29051.
[8]NAKAMURA K,NISHIMURA J,HIRANO K,et al.Hydroxyfasudil,an active metabolite of fasudil hydrochloride,relaxes the rabbit basilar artery by disinhibition of myosin light chain phosphatase[J].J Cereb Blood Flow Metab,2001,21(7):876-885.DOI:10.1097/00004647-200107000-00013.
[9]WOLFRUM S,DENDORFER A,RIKITAKE Y,et al.Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection[J].Arterioscler Thromb Vasc Biol,2004,24(10):1842-1847.DOI:10.1161/01.ATV.0000142813.33538.82.
[10]AHMED L A,DARWISH H A,ABDELSALAM R M,et al.Role of Rho kinase inhibition in the protective effect of fasudil and simvastatin against 3-nitropropionic acid-induced striatal neurodegeneration and mitochondrial dysfunction in rats[J].Mol Neurobiol,2016,53(6):3927-3938.DOI:10.1007/s12035-015-9303-2.
[11]HIGASHI M,SHIMOKAWA H,HATTORI T,et al.Long-term inhibition of Rho-kinase suppresses angiotensin Ⅱ-induced cardiovascular hypertrophy in rats in vivo:effect on endothelial NAD(P)H oxidase system[J].Circ Res,2003,93(8):767-775.DOI:10.1161/01.RES.0000096650.91688.28.
[12]MA G,BI S.Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease[J].Exp Ther Med,2019,17(1):332-336.DOI:10.3892/etm.2018.6923.
[13]KUMAR B,SHAH M A A,KUMAR R,et al.Comparison of atorvastatin and rosuvastatin in reduction of inflammatory biomarkers in patients with acute coronary syndrome[J].Cureus,2019,11(6):e4898.DOI:10.7759/cureus.4898.
[14]LAUFS U,LA FATA V,PLUTAKY J,et a1.Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors[J].Circulation,1998,97(12):1129-1135.DOI:10.1161/01.cir.97.12.1129.
[15]NOMA K,KIHARA Y,HIGASHI Y,et al.Striking crosstalk of ROCK signaling with endothelial function[J].J Cardiol,2012,60(1):1-6.DOI:10.1016/j.jjcc.2012.03.005.